Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Publication
, Journal Article
Becker, RC; Alexander, J; Dyke, CK; Harrington, RA
Published in: Thrombosis and haemostasis
December 2004
The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin - a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitations of currently available anticoagulants, has led to the development of pharmacologic inhibitors of this important protease. The following review focuses on DX-9065a - first in a class of direct, selective and reversible fXa antagonists - and its potential applications in the management of patients with cardiovascular disease.
Duke Scholars
Published In
Thrombosis and haemostasis
DOI
EISSN
2567-689X
ISSN
0340-6245
Publication Date
December 2004
Volume
92
Issue
6
Start / End Page
1182 / 1193
Related Subject Headings
- Time Factors
- Thrombosis
- Thromboplastin
- Thrombin
- Rats
- Propionates
- Platelet Aggregation Inhibitors
- Pilot Projects
- Naphthalenes
- Models, Chemical
Citation
APA
Chicago
ICMJE
MLA
NLM
Becker, R. C., Alexander, J., Dyke, C. K., & Harrington, R. A. (2004). Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thrombosis and Haemostasis, 92(6), 1182–1193. https://doi.org/10.1160/th04-05-0289
Becker, Richard C., John Alexander, Christopher K. Dyke, and Robert A. Harrington. “Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.” Thrombosis and Haemostasis 92, no. 6 (December 2004): 1182–93. https://doi.org/10.1160/th04-05-0289.
Becker RC, Alexander J, Dyke CK, Harrington RA. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thrombosis and haemostasis. 2004 Dec;92(6):1182–93.
Becker, Richard C., et al. “Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.” Thrombosis and Haemostasis, vol. 92, no. 6, Dec. 2004, pp. 1182–93. Epmc, doi:10.1160/th04-05-0289.
Becker RC, Alexander J, Dyke CK, Harrington RA. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thrombosis and haemostasis. 2004 Dec;92(6):1182–1193.
Published In
Thrombosis and haemostasis
DOI
EISSN
2567-689X
ISSN
0340-6245
Publication Date
December 2004
Volume
92
Issue
6
Start / End Page
1182 / 1193
Related Subject Headings
- Time Factors
- Thrombosis
- Thromboplastin
- Thrombin
- Rats
- Propionates
- Platelet Aggregation Inhibitors
- Pilot Projects
- Naphthalenes
- Models, Chemical